Background:Precision oncology treatments are being applied more commonly in breast and gynecological oncology through the implementation of Molecular Tumor Boards (MTBs), but real-world clinical outcome data remain limited.Methods:A retrospective analysis was conducted in patients with breast cancer (BC) and gynecological malignancies referred to our center’s MTB from 2018 to 2023. The analysis covered patient characteristics, next-generation sequencing (NGS) results, MTB recommendations, therapy received, and clinical outcomes.Results:Sixty-three patients (77.8%) had metastatic disease, and forty-four patients (54.3%) had previously undergone three or more lines of systemic treatment. Personalized treatment recommendations were provided to 50 patients (63.3%), while 29 (36.7%) had no actionable target. Ultimately, 23 patients (29.1%) underwent molecular-matched treatment (MMT). Commonly altered genes in patients with pan-gyn tumors (BC and gynecological malignancies) includedTP53(n= 42/81, 51.9%),PIK3CA(n= 18/81, 22.2%),BRCA1/2(n= 10/81, 12.3%), andARID1A(n= 9/81, 11.1%). Patients treated with MMT showed significantly prolonged progression-free survival (median PFS 5.5 vs. 3.5 months,p= 0.0014). Of all patients who underwent molecular profiling, 13.6% experienced a major clinical benefit (PFSr ≥ 1.3 and PR/SD ≥ 6 months) through precision oncology.Conclusions:NGS-guided precision oncology demonstrated improved clinical outcomes in a subgroup of patients with gynecological and breast cancers.
背景：通过实施分子肿瘤委员会（MTB），精准肿瘤治疗在乳腺和妇科肿瘤领域正得到更广泛的应用，但真实世界的临床结局数据仍然有限。方法：本研究对2018年至2023年间转诊至我院MTB的乳腺癌及妇科恶性肿瘤患者进行了回顾性分析。分析内容包括患者特征、二代测序（NGS）结果、MTB建议、实际接受的治疗方案及临床结局。结果：63例患者（77.8%）存在转移性疾病，44例患者（54.3%）既往接受过三线及以上系统治疗。50例患者（63.3%）获得了个体化治疗建议，29例（36.7%）未发现可干预靶点。最终，23例患者（29.1%）接受了分子匹配治疗（MMT）。全妇科肿瘤（包括乳腺癌及妇科恶性肿瘤）患者中常见突变基因包括TP53（42/81例，51.9%）、PIK3CA（18/81例，22.2%）、BRCA1/2（10/81例，12.3%）和ARID1A（9/81例，11.1%）。接受MMT治疗的患者无进展生存期显著延长（中位PFS 5.5个月 vs 3.5个月，p=0.0014）。在所有接受分子谱分析的患者中，13.6%通过精准肿瘤治疗获得显著临床获益（PFS比值≥1.3且部分缓解/疾病稳定≥6个月）。结论：NGS指导的精准肿瘤治疗在部分妇科及乳腺癌患者亚群中展现出改善临床结局的潜力。
肿瘤(癌症)患者之家